Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Pharmadrug Inc C.PHRX

Alternate Symbol(s):  LMLLF

Medical Care Cannabis
PharmaDrug Inc. is a Canada-based specialty pharmaceutical company. The Company is focused on the research, development and commercialization of controlled-substances and natural medicines, such as psychedelics and previously approved drugs. The Company’s subsidiary, Sairiyo Therapeutics (Sairiyo), is a biotech company that specializes in researching and reformulating established natural medicines. Sairiyo is engaged in the development of its patented reformulation of cepharanthine, a drug that has shown substantial third party validated potential for the treatment of infectious diseases (including Covid-19) and rare cancers. In clinical research, Cepharanthine exhibits multiple pharmacological effects, including anti-oxidative, anti-inflammatory, immuno-regulatory, anti-cancer, anti-viral and anti-parasitic properties. Sairiyo is also conducting research and development (R&D) in the psychedelics space for the treatment of non-neuropsychiatric conditions.


CSE:PHRX - Post by User

Pharmadrug Inc > SamRothstein
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(15)
•••
Comment by SamRothsteinon Apr 14, 2021 1:09pm
41 Views
Post# 32993523

RE:RE:RE:RE:SamRothstein

RE:RE:RE:RE:SamRothsteinJeff, exactly how dumb do you think the people that read these posts are?  You want to talk about the fact you were only able to get 2% of the IPO at 10 cents and pretend that you and your friends and family didn't make out like a bandit?  Please stop insulting out intelligence.   It would also be a lot more becoming for a person in your station (or anyone in any station for that matter) if you could refrain from your repeated, unwarranted, ad hominem attacks on people that simply don't agree with you.  I know it is a childish sounding word, but I do find it just plain gross that you hind behind the libel laws that allow you to insult people that don't want their names published online.  While it might be legal to slander people's pseudonyms, there are still rules of common decency and manners, which one would hope that someone in your position is at least someone acquainted with.  

JefffCEO wrote: Sam .. your wrong again!  IPO of GRB was 10 cents and I was limited to 2% of the IPO per CPC rules.  Now crawl back into your world of pumping and dumping.  


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities